These are reviewer questions, dealt with at the time of filing with the reviewing branch. They are
not issues for Q7A. Whether or not there are established specifications for these parameters
would already have been determined in the filing. It should be noted that for an API that is
obviously intended for parenteral drug manufacturing, microbiological and endotoxin issues are
relevant.
